Marianne K O Grant

List of Publications by Year
in descending order

39 papers	1,797 citations	777949 13 h-index	488211 31 g-index
40 all docs	40 docs citations	40 times ranked	3585 citing authors

#	Article	IF	Citations
1	Divergent Cardiac Effects of Angiotensin II and Isoproterenol Following Juvenile Exposure to Doxorubicin. Frontiers in Cardiovascular Medicine, 2022, 9, 742193.	1.1	3
2	EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263. Cells, 2022, 11, 1992.	1.8	8
3	Metformin Modulates Doxorubicinâ€induced Senescence Phenotype in Endothelial Cells. FASEB Journal, 2021, 35, .	0.2	1
4	Doxorubicin Paradoxically Ameliorates Tumor-Induced Inflammation in Young Mice. International Journal of Molecular Sciences, 2021, 22, 9023.	1.8	3
5	Identification of new candidate biomarkers to support doxorubicin treatments in canine cancer patients. BMC Veterinary Research, 2021, 17, 378.	0.7	4
6	Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. PLoS ONE, 2020, 15, e0232507.	1.1	21
7	CYP1B1 as a therapeutic target in cardio-oncology. Clinical Science, 2020, 134, 2897-2927.	1.8	21
8	Sexual Dimorphism in Doxorubicin-induced Systemic Inflammation: Implications for Hepatic Cytochrome P450 Regulation. International Journal of Molecular Sciences, 2020, 21, 1279.	1.8	13
9	Doxorubicin Cardiotoxicity in Young Tumorâ€Bearing Mice. FASEB Journal, 2020, 34, 1-1.	0.2	0
10	Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. , 2020, 15, e0232507.		0
11	Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. , 2020, 15, e0232507.		0
12	Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. , 2020, 15, e0232507.		0
13	Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. , 2020, 15, e0232507.		0
14	Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. , 2020, 15, e0232507.		0
15	Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. , 2020, 15, e0232507.		0
16	A Cautionary Tale: Endogenous Biotinylated Proteins and Exogenously-Introduced Protein A Cause Antibody-Independent Artefacts in Western Blot Studies of Brain-Derived Proteins. Biological Procedures Online, 2019, 21, 6.	1.4	9
17	Leveraging the Cardio-Protective and Anticancer Properties of Resveratrol in Cardio-Oncology. Nutrients, 2019, 11, 627.	1.7	27
18	Human cerebrospinal fluid 6E10-immunoreactive protein species contain amyloid precursor protein fragments. PLoS ONE, 2019, 14, e0212815.	1.1	12

#	Article	IF	Citations
19	Sexual dimorphism of acute doxorubicin-induced nephrotoxicity in C57Bl/6 mice. PLoS ONE, 2019, 14, e0212486.	1.1	21
20	Sexually Dimorphic Regulation of Renal Soluble Epoxide Hydrolase by Acute Doxorubicinâ€Induced Toxicity. FASEB Journal, 2019, 33, 678.8.	0.2	0
21	Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes. Cardiovascular Research, 2018, 114, 1350-1359.	1.8	41
22	Anticancer effects of resveratrol in canine hemangiosarcoma cell lines. Veterinary and Comparative Oncology, 2018, 16, 253-261.	0.8	17
23	Psychosocial stress unmasks latent doxorubicin-induced cardiotoxicity. Journal of Molecular and Cellular Cardiology, 2018, 124, 93-94.	0.9	2
24	Sex-dependent alteration of cardiac cytochrome P450 gene expression by doxorubicin in C57Bl/6 mice. Biology of Sex Differences, 2017, 8, 1.	1.8	35
25	Quaternary Structure Defines a Large Class of Amyloid-Î² Oligomers Neutralized by Sequestration. Cell Reports, 2015, 11, 1760-1771.	2.9	141
26	Brain amyloid-Î² oligomers in ageing and Alzheimerâ€™s disease. Brain, 2013, 136, 1383-1398.	3.7	384
27	Correlation of Specific Amyloid-Î² Oligomers With Tau in Cerebrospinal Fluid From Cognitively Normal Older Adults. JAMA Neurology, 2013, 70, 594.	4.5	54
28	Pharmacological Evaluation of the Long-Term Effects of Xanomeline on the M1 Muscarinic Acetylcholine Receptor. PLoS ONE, 2010, 5, e15722.	1.1	6
29	Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration. Neuron, 2010, 68, 1067-1081.	3.8	859
30	Mechanisms of M3 Muscarinic Receptor Regulation by Wash-Resistant Xanomeline Binding. Pharmacology, 2009, 83, 301-317.	0.9	4
31	Immediate and Delayed Consequences of Xanomeline Wash-Resistant Binding at the M3 Muscarinic Receptor. Neurochemical Research, 2009, 34, 1138-1149.	1.6	3
32	Synthesis and evaluation of xanomeline analogsâ€”Probing the wash-resistant phenomenon at the M1 muscarinic acetylcholine receptor. Bioorganic and Medicinal Chemistry, 2008, 16, 1376-1392.	1.4	33
33	Long-Term Changes in the Muscarinic M1 Receptor Induced by Instantaneous Formation of Wash-Resistant Xanomeline-Receptor Complex. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 868-876.	1.3	6
34	Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor. Neuroscience Letters, 2006, 410, 11-14.	1.0	6
35	Persistent Binding and Functional Antagonism by Xanomeline at the Muscarinic M5 Receptor. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 313-319.	1.3	33
36	Therapeutic interventions targeting the nitric oxide system: Current and potential uses in obstetrics, bone disease and erectile dysfunction. Life Sciences, 2004, 74, 1701-1721.	2.0	8

#	Article	IF	Citations
37	Endogenous expression of nNOS protein in several neuronal cell lines. Life Sciences, 2002, 71, 813-817.	2.0	11
38	Transducer abstraction. Journal of Pharmacological and Toxicological Methods, 2000, 43, 55-67.	0.3	6
39	Regulation of acetylcholine binding by ATP at the muscarinic M1 receptor in intact CHO cells. Brain Research, 1999, 839, 94-99.	1.1	5